C84.77 Anaplastic large cell lymphoma, ALK-negative, spleen

Name of the Condition

• Anaplastic large cell lymphoma, ALK-negative, spleen (ICD-10 Code: C84.77)

Summary

Anaplastic large cell lymphoma (ALCL), ALK-negative, spleen, is a rare type of non-Hodgkin lymphoma that originates from T-cells or null cells. It is characterized by the presence of large, abnormal lymphoid cells and typically presents as a systemic disease, though cutaneous involvement may occur. The condition is aggressive and requires prompt evaluation and management.

Causes

The exact cause of ALK-negative ALCL is not fully understood. It is believed to involve genetic mutations in lymphoid cells, which lead to uncontrolled growth and accumulation. Environmental factors or chronic antigen stimulation may contribute to its development, though specific triggers remain unclear.

Risk Factors

• Age: More common in adults, particularly those over 60.
• Immunosuppression: Conditions or treatments that weaken the immune system.
• Genetic predispositions: Family history of lymphoma or related disorders.
• Prior lymphoid disorders: History of other lymphoid malignancies may increase risk.

Symptoms

• Swollen lymph nodes or masses in affected areas.
• Fever, night sweats, and unexplained weight loss (B symptoms).
• Skin lesions, rashes, or nodules (if cutaneous involvement is present).
• Fatigue, loss of appetite, and general malaise.
• Organ-specific symptoms (e.g., abdominal pain or discomfort if the spleen is involved).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or MRI), and biopsy of affected tissue (e.g., lymph node or spleen). Histopathological examination confirms the presence of large, abnormal lymphoid cells, and immunohistochemistry helps differentiate ALK-negative ALCL from other lymphomas. Additional tests, such as flow cytometry or molecular studies, may be used to assess genetic markers.

Treatment Options

Treatment typically includes systemic chemotherapy, often with regimens used for other aggressive lymphomas. Targeted therapies or immunotherapy may be considered based on individual patient factors. In some cases, radiation therapy or splenectomy (surgical removal of the spleen) may be part of the treatment plan. Clinical trials may offer additional options for eligible patients.

Prognosis and Follow-Up

Prognosis varies depending on factors such as age, overall health, and response to treatment. ALK-negative ALCL is generally more aggressive than its ALK-positive counterpart, and outcomes may be less favorable. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression.

Complications

• Disease progression or recurrence.
• Infection due to immunosuppression from treatment.
• Organ dysfunction (e.g., splenic rupture or impaired organ function from tumor burden).
• Treatment-related side effects (e.g., cytopenias, neuropathy).

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid known carcinogens and limit alcohol consumption.
• Stay up-to-date with vaccinations, especially if immunosuppressed.
• Seek prompt medical attention for persistent symptoms.

When to Seek Professional Help

Consult a healthcare provider if you experience unexplained weight loss, persistent fever, night sweats, or swollen lymph nodes. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

When coding for C84.77, ensure the documentation specifies the spleen as the primary site of involvement. Verify that the diagnosis aligns with ALK-negative status and that no other site-specific codes are applicable. Accurate documentation of the anatomical location and lymphoma type is essential for correct code assignment.